Results 51 to 60 of about 47,580 (341)
Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting
Molecular Oncology, EarlyView.CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia +9 more
wiley +1 more source
Experimental Hematology & Oncology, 2017 HER2-targeted immunotherapy consists of monoclonal antibodies (e.g. trastuzumab, pertuzumab), bispecific antibodies (e.g. MM-111, ertumaxomab) and activated T cells armed with anti-HER2 bispecific antibody (HER2Bi-aATC). Trastuzumab is a classic drug for
Shengnan Yu +6 more
doaj +1 more source
Targeting and killing of glioblastoma with activated T cells armed with bispecific antibodies [PDF]
, 2013 Background Since most glioblastomas express both wild-type EGFR and EGFRvIII as well as HER2/neu, they are excellent targets for activated T cells (ATC) armed with bispecific antibodies (BiAbs) that target EGFR and HER2.
A Formentini +51 more
core +2 more sources
Molecular Oncology, EarlyView.The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg +43 more
wiley +1 more source
Detection of CD33 expression on monocyte surface is influenced by phagocytosis and temperature [PDF]
, 2019 CD33 is a myeloid-associated marker and belongs to the sialic acid-binding immunoglobulin (Ig)-like lectin (Siglec) family. Such types of receptors are highly expressed in acute myeloid leukemia, which could be used in its treatment.
Baisaeng, Nuttakorn +7 more
core +1 more source
Bispecific antibodies and their applications [PDF]
Journal of Hematology & Oncology, 2015 Bispecific antibodies (BsAbs) recognize two different epitopes. This dual specificity opens up a wide range of applications, including redirecting T cells to tumor cells, blocking two different signaling pathways simultaneously, dual targeting of different disease mediators, and delivering payloads to targeted sites.
Fan, Gaowei +3 more
openaire +2 more sources
Cotargeting TREM2 and IL2 pathways triggers multipronged anticancer immunity
Molecular Oncology, EarlyView.Von Locquenghien et al. report that MiTE‐144, a triggering receptor expressed on myeloid cells 2 (TREM2) blocking antibody fused to interleukin‐2 (IL2) variant with tumour microenvironment restricted activation, demonstrates superior anticancer efficiency in a preclinical setting.
Isaure Vanmeerbeek +2 more
wiley +1 more source
Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity. [PDF]
PLoS ONE, 2013 In hemophilia A, routine prophylaxis with exogenous factor VIII (FVIII) requires frequent intravenous injections and can lead to the development of anti-FVIII alloantibodies (FVIII inhibitors).
Zenjiro Sampei +18 more
doaj +1 more source
Bispecific Antibodies Against HIV [PDF]
Cell, 2016 Synergistic bispecific antibodies against HIV exhibit extraordinary potency and breadth of neutralization as promising candidates for treatment and prevention.
openaire +2 more sources
FEBS Open Bio, EarlyView.Tandem VHH targeting distinct EGFR epitopes were engineered into a monovalent bispecific antibody (7D12‐EGA1‐Fc) with more potent ADCC without increasing affinity to EGFR. Structural modeling of 7D12‐EGA1‐Fc showed cross‐linking of separate EGFR domains to enhance CD16a engagement on NK cells.
Yuqiang Xu +5 more
wiley +1 more source